They found that newly diagnosed, treatment naïve SLE patients had an association with distinct monocyte cytokine signatures with high monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein 1β (Mip1β) and interleukin-1 receptor antagonist (IL-1RA). Here, IL6R is linked to systemic lupus erythematosus.